HOME
SEARCH
RSS FEED
SUBSCRIBE
Novel Small Molecule Agonists of the Relaxin Receptor as Potential Therapy for Heart Failure and Fibrosis
Case ID:
TAB-2498
Web Published:
12/6/2022
Description:
The present invention is directed to novel small molecule agonists of the mammalian relaxin family receptor 1 (RXFP1), including human RXFP1. Activation of RXFP1 induces: 1) vasodilation due to up-regulation of the endothelin system; 2) extracellular matrix remodeling; 3) moderation of inflammation by reducing levels of inflammatory cytokines; and 4) angiogenesis. Small molecule agonists of RXFP1 may be useful in treating acute heart failure (AHF), scleroderma, fibrosis, other conditions associated with the biology of relaxin, and in improving reproductive health and wound healing. These compounds are the first and only small molecule agonists of RXFP1.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Novel_Small_Molecule_Agonists_of_the _Relaxin_Receptor_as_Potential_Therapy_for_Heart_Failure_and_Fibrosis
Category(s):
Collaboration
Therapeutics
Vaccines
Cardiology
Reproductive Health
Immunology
Research Materials
Diagnostics
Bookmark this page
Download as PDF
For Information, Contact:
Jasmine Kalsi
LPM
NIH Technology Transfer
301-435-0129
jasmine.kalsi@nih.gov
Inventors:
Wei Zheng
Marc Ferrer-Alegre
Catherine Chen
Alexander Agoulnik
Noel Southall
Jingbo Xiao
Juan Marugan
Keywords:
1
IB1XXX
IB3XXX
IB5XXX
IB6XXX
IBXXXX
IXXXXX
MODULATORS
POTENT
RECEPTOR
Relaxin
RXFP1
SELECTIVE
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum